Search Results 1221-1230 of 17077 for monoclonal antibody

  1. Chronic lymphocytic leukemia - Diagnosis and treatment - Mayo Clinic

    Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood. 2021; doi:10.1182/blood.2020006322. Related. Associated Procedures.

  2. The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH) - Mayo Clinic

    NMDAR encephalitis is a life‑threatening, antibody-mediated autoimmune disorder of the central nervous system. Standard of care includes high-dose ...

  3. Infliximab Response in Inflammatory Bowel Disease - Mayo Clinic

    ... antibodies-to-infliximab, and evaluate how soon after initiation of therapy there is development of antibodies-to-infliximab. Participation eligibility.

  4. Hematology - Clinical trials

    ... antibodies and the factors that may determine disease progression and treatment response. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating ...

  5. Biosensors and microdevices for clinical sample testing - Cellular Microsystems and Biosensors Laboratory - Mayo Clinic Research

    Over the years, we have developed a range of approaches for analyzing extracellular vesicles, cytokines and disease-specific antibodies from clinical samples.

  6. Interpreting the News: COVID-19 Experimental Vaccines

    What is the significance of the BNT162b2 vaccine reportedly causing both antibodies and T cells to be made by the host? The immune system has two arms: humoral ...

  7. Publications - Alessia Buglioni, M.D. - Mayo Clinic

    Vargas-Brochero MJ, Buglioni A, Mekraksakit P, Thongparyoon C, Inacio A, Domingues P, Fervenza FC, Zand L. Monoclonal Gammopathy in ANCA-Negative Pauci ...

  8. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

    ... monoclonal antibody (mAb) therapy within 45 days prior to study Day 1. Note: Patients are allowed to receive any of the following treatments up to 7 days ...

  9. A Study To Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC - Mayo Clinic

    History of severe hypersensitivity reactions to monoclonal antibodies, which ... antibody or drug specifically targeting T-cell co-stimulation or ...

  10. Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer - Mayo Clinic

    NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment (cytotoxics, monoclonal antibodies, small molecule ...